Hepatocyte nuclear factor 4a (HNF4a) is essential for the establishment and maintenance of liver-specific gene expression. The HNF4a gene codes for several isoforms whose developmental and physiological relevance has not yet been explored. HNF4a1 and HNF4a7 originate from different promoters, while alternative splicing in 3 0 leads to HNF4a2 and HNF4a8, respectively. HNF4a7/a8 were abundantly expressed in embryonic liver and fetal-like hepatoma cells. HNF4a1/a2 transcripts were up-regulated at birth and represented the only isoforms in adult-like hepatoma cells. In line with its expression profile, HNF4a7 activated more avidly than HNF4a1 reporter plasmids for genes that are expressed early. The expression patterns of both isoforms together with the differences observed in their transcriptional activities provide elements accounting for fine-tuning of the activity of HNF4a. The sequential expression of HNF4a7/a8 and HNF4a1/a2 during mouse liver development is the only modification in liver-enriched transcription factors thus far recorded, which parallels the transition from the fetal to the adult hepatic phenotype. q
Introduction
The liver originates from foregut ventral endoderm and is induced by signals from the cardiac mesoderm at the sixsomite stage of the mouse embryo (Le Douarin, 1975) . Early presumptive hepatic cells proliferate and migrate into the septum transversum to form the liver diverticulum, which undergoes extensive growth, migration and morphogenesis. Development of the liver results from two processes: specific gene expression and acquisition of a defined morphological identity. The onset of liver-specific gene expression occurs at 8.5 days post-coitum (d.p.c.) and is demarcated by the presence of alpha-fetoprotein and albumin transcripts (Gualdi et al., 1996) . Changes in gene expression occur in response to the activation of liverenriched transcription factors (LETF) that were originally identified by their ability to bind regulatory elements of genes expressed in the liver.
These families of factors include hepatocyte nuclear factor 1 (HNF1), HNF3, HNF4, and CCAAT/enhancer binding protein (C/EBP). There exist several genes within each family, and for some of them, protein isoforms have been identified. Members of all these families play a determinant role in the development of the embryo and/or in liver homeostasis since inactivation of the corresponding genes provokes embryonic lethality in the cases of HNF1b (Barbacci et al., 1999; Coffinier et al., 1999) , HNF3b (Ang and Rossant, 1994) and HNF4a or results in seriously compromised liver function when HNF1a (Pontoglio et al., 1996) or C/EBPa is absent (Wang et al., 1995) .
The transcription factors that are essential for development are usually also required for maintenance of gene expression in the adult. Moreover, they could play distinct roles in controlling gene expression during embryonic and adult life. Differential expression from distinct genes of proteins having the same DNA binding properties, as is the case for the HNF1 and HNF3 gene families, could account for such dual roles. For C/EBPa the translation from alternative initiation methionines in the newborn results in the synthesis of isoforms showing different transcriptional activities (Ossipow et al., 1993) . In addition, C/EBPa transcripts are strongly up-regulated at birth (Wang et al., 1995) . However, the mechanisms that enable the same factor to play distinct roles in controlling gene expression during embryonic and adult life have mostly not yet been explored.
HNF4a induces HNF1a transcription in hepatoma cell lines and these are the only factors whose expression strictly correlates with the differentiation state of hepatoma cells (Bulla and Fournier, 1994; Kuo et al., 1992; Späth and Weiss, 1997) . Nonetheless, only HNF4a has been shown to play an essential role in liver development and hepatocyte differentiation in vivo (Li et al., 2000) . Its expression in the mouse embryo begins at 9.5 d.p.c. but transcripts of HNF4a are detected in the primitive endoderm from 4.5 d.p.c. . Invalidation of the gene causes embryonic lethality at 6.5 d.p.c. HNF4a 2 /2 embryos are unable to complete gastrulation due to a dysfunctional visceral endoderm accompanied by ectodermal cell death . The gastrulation incompetence can be rescued in tetraploid aggregation embryos where the extra-embryonic tissues, including the visceral endoderm, are composed of wild-type tetraploid cells. Nevertheless, the mutant hepatocytes fail to achieve normal expression levels of an entire set of liver functions . Furthermore, in the adult, liverspecific invalidation of the HNF4a gene provokes disorders in lipid metabolism (Hayhurst et al., 2001 ) and mutations in the gene have been associated with MODY-1, a non-insulin-dependent diabetes mellitus characterized by an early-onset (Stoffel and Duncan, 1997) . All of these data indicate that HNF4a performs essential roles in regulating hepatic transcription during embryonic, fetal and adult life.
HNF4a is an orphan nuclear receptor of the steroid/thyroid hormone receptor superfamily originally purified from rat liver (Sladek et al., 1990) . Several HNF4a isoforms are known, HNF4a1 being the first to be characterized (reviewed in Sladek and Seidel, 2001 ). HNF4a7 was originally cloned from a murine cell line (Nakhei et al., 1998) and we identified its rat counterpart (Torres-Padilla et al., GeneBank AF329936) . This isoform contains a unique set of N-terminal amino acids and is translated from an alternative first exon with a different 5 0 -UTR as compared to HNF4a1; its transcription was assumed to be regulated by an alternative promoter (Nakhei et al., 1998) . Most studies to address HNF4a function and regulation have relied upon probes and models that fail to differentiate among isoforms. Hence, the developmental and physiological relevance of HNF4a isoforms has not yet been explored. Because HNF4a is a key factor in liver development, we have initiated analysis of its isoforms in hepatoma cells and in mouse liver throughout development, focusing on four isoforms that are good candidates to play distinct roles. Firstly, since HNF4a1 and HNF4a7 transcripts are initiated from distinct promoters, expression of these isoforms could be controlled by different sets of transcription factors. Secondly, alternative splicing can lead to different Ctermini of the HNF4a protein, giving rise to proteins that do or do not contain a ten amino acid insertion that may act to alleviate a repressive function of the C-terminal domain and modify ability of the proteins to recruit co-activators (Sladek et al., 1999) . HNF4a1 and HNF4a7 do not contain this insertion. The alternatively spliced variant for HNF4a1 has been called HNF4a2 and the postulated one from HNF4a7 is HNF4a8.
We demonstrate that during mouse liver development transcripts originating from the different promoters are expressed in sequential fashion, those for HNF4a7/a8 being present throughout development while the HNF4a1/ a2 transcripts become abundant only at birth. In line with these results, we show that HNF4a7 is a better transactivator than HNF4a1 of reporters for genes that are expressed early. The temporal expression patterns of both isoforms coupled with the differences in their transcriptional activities provide novel insights into the roles of HNF4a isoforms during liver development.
Results

HNF4a gene organization and known or predicted isoforms
The HNF4a protein is coded by ten exons. Fig. 1 shows the structure of the gene and the different isoforms that may result from alternative promoter usage and differential splicing. Exon 1A corresponds to the first exon originally described for HNF4a1 and its transcripts will be referred to as originating from the HNF4a1 promoter. The alternative first exon of HNF4a7 will be hereafter referred to as exon 1D (exons 1B and 1C have already been described in human cDNA) (Drewes et al., 1996; Furuta et al., 1997; reviewed in Sladek and Seidel, 2001) , and its transcripts will be referred to as originating from the HNF4a7 promoter.
The isoform HNF4a2 results from the utilization of a second donor site in exon 9, leading to a protein ten amino acids longer than HNF4a1 (Hata et al., 1992) . Since existence of the predicted HNF4a8 isoform has never been heretofore demonstrated, we verified its presence using RNA from hepatoma cells that contain transcripts originating from the HNF4a7 promoter. cDNA was synthesized and polymerase chain reaction (PCR) carried out with the forward primer of exon 1D and the most 3 0 reverse primer (Fig. 1B) . This led to two HNF4a products that migrate together (1321 and 1291 bp) that can be distinguished because the 30 nucleotide sequence contains a unique BglI site. Indeed, when the products were digested by BglI, three bands were obtained: one band of 1291 bp corresponding to the HNF4a7 cDNA and two bands of 1201 and 120 bp, corresponding to the BglI-digested HNF4a8 cDNA (Fig. 1C) . These results provide clear evidence for the existence of transcripts for this isoform.
2.2. HNF4a 1 is expressed in hepatoma cells with an adult phenotype while HNF4a 7 expression correlates with a fetal phenotype
The differential expression of HNF4a1 and HNF4a7 was initially documented in MHSV-12 cells that had or had not been induced to differentiate by treatment with dexamethasone (Nakhei et al., 1998) . To pursue analysis of the relationship between expression of these two isoforms of HNF4a and the differentiation state of liver cells, we focused on well-characterized hepatoma cells. These hepatoma lines fall into three categories: cells of fetal phenotype which produce AFP as well as a set of secreted serum proteins; cells of adult phenotype which no longer express the AFP gene, continue to produce serum proteins, and show activation of expression of a set of functions important for the metabolic activities of adult liver; dedifferentiated variant cells which fail to express the majority of hepatic functions. We therefore analyzed the expression of HNF4a1 and HNF4a7 by reverse transcriptase polymerase chain reaction (RT-PCR) in representative clones of the different phenotypes using specific forward primers to distinguish between exons 1A and 1D. A common reverse primer was used (Fig. 1B) .
Previous work has not revealed a difference in the expression patterns of the LETF in hepatoma cells of fetal versus adult phenotype. Indeed, both types of cells produce HNF4a, HNF1a, HNF3a, b and g, and C/EBPa (Angrand et al., 1994; Faust et al., 1994) . These identical profiles of LETF expression have made it difficult to understand the mechanisms responsible for the major differences in gene expression patterns of the two types of hepatoma lines. However, when we examined the isoforms of HNF4a resulting from alternative promoter usage, a striking difference was finally identified.
BW1J hepatoma cells are considered to present a fetal hepatic phenotype since they express AFP and TTR, but no ApoCIII or PAH (Fig. 2B) . RT-PCR analysis showed that they express exclusively transcripts originating from the HNF4a7 promoter ( Fig. 2A) . On the other hand, Fao and FGC4 cells are of adult hepatic phenotype for they fail to express AFP but have activated expression of the ApoCIII and PAH genes (Fig. 2B ). For these cell lines, only the product corresponding to the amplification of exon 1A was detected, implying that only transcripts originating from the HNF4a1 promoter are produced. H5 is a dedifferentiated hepatoma cell line that does not express any HNF4a (Fig. 2B ). These results demonstrate a strict correlation between transcription from the HNF4a7 promoter and expression of a fetal hepatic phenotype, and from the HNF4a1 promoter and of an adult hepatic phenotype in hepatoma cell lines. To determine whether this correlation holds during mouse liver development, the expression of the HNF4a isoforms was examined in embryonic, fetal, and newborn liver. As shown in the figure, transcripts for exon 1A and 1D sequences were present consistently. Remarkably, exon 1D usage was predominant until 18.5 d.p.c. At this time, expression of exon 1A increased dramatically and reached a maximum at birth (Fig. 3A) , a pattern of transcript accumulation reminiscent of that of 'neonatal' hepatic functions. No striking changes in the level of expression of exon 1D during development were observed. Thus, during early liver development HNF4a transcripts initiate from the HNF4a7 promoter, and the HNF4a1 promoter transcripts become abundant only at the time of birth.
Alternative splicing at the 3 0 end of HNF4a transcripts occurs constitutively
We also studied the presence of the insertion of 30 nucleotides within the sequence encoding the F domain, using primers located 5 0 and 3 0 of this insertion leading to PCR products of either 177 or 207 bp (Fig. 3B) . In contrast to the quasi-exclusive transcription from the exon 1D promoter during embryonic and fetal stages followed by the gradual replacement by exon 1A promoter usage at birth, the transcripts resulting from alternative splicing were systematically observed and in roughly the same proportions throughout development (Fig. 3B ). HNF4a2/ a8 transcripts were present in higher amounts than those of HNF4a1/a7, exhibiting a more or less constant ratio. As mentioned above, the longer transcripts result from the usage of a second donor site within exon 9. Thus, this alternative splicing involving the inclusion or not of the 30 nucleotides appears to be constitutive, regardless of the developmental stage of the liver, and the longer transcripts are always majority.
The pattern of transcript accumulation in developing liver is paralleled by that of the corresponding proteins
Using an antiserum (aN1.14) that recognizes the N-terminal region of HNF4a1/a2 but not of HNF4a7/a8, HNF4a was not detected in Western blots with total extracts from liver at 12.5 and 16.5 d.p.c., when mainly HNF4a7/a8 transcripts were detected (Fig. 3D) . Thereafter, an HNF4a1/a2 specific band appears and shows a sharp increase around birth. At early stages of liver development when mainly HNF4a7 transcripts were detected, others have demonstrated by gelshift and supershift analyses that HNF4a protein is present (Cereghini et al., 1992) . Thus, it can be concluded that the HNF4a transcripts are translated throughout liver development.
These studies have revealed that exons 1A and 1D are differentially expressed in liver during the course of development. The results suggest that in vivo HNF4a7/a8 are embryonic isoforms that could be important for the acquisition and maintenance of an embryonic/fetal phenotype in hepatocytes. The alternative promoter usage that leads to the expression of exon 1A or exon 1D is regulated in a birthrelated fashion, with HNF4a1/a2 increasing dramatically at this time. This regulation may be involved in the establishment of a balance of HNF4a isoforms required for the activation of hepatic functions during the perinatal period. It should be pointed out that this is a critical period, since the liver must assume the functions necessary to render metabolism of the newborn independent of maternal circulation.
HNF4a 1 and HNF4a7 dimerize when bound to DNA
HNF4a binds DNA as a homodimer (Jiang et al., 1995) . The results presented have shown that four isoforms are present simultaneously in the liver just prior to birth. Assuming that the same hepatocytes synthesize these isoforms, it is important to know whether they are able to dimerize or whether they remain as distinct pools. We limited experiments to the HNF4a1-HNF4a7 forms, considering that the results can be extrapolated to other possible dimers since the a1-a2 isoforms have already been shown to dimerize (Sladek et al., 1999) .
NIH3T3 cells were transfected with CMV.HNF4a1.VSV and/or CMV.HNF4a7.VSV plasmids and cell extracts were analyzed by electrophoretic mobility shift assay (EMSA) and Western blot (Fig. 4) . When expressed alone, each of the isoforms bound specifically to the C3P oligonucleotide giving rise to a retarded complex (Fig. 4A, lanes 2 and 6) . The amount of HNF4a protein present in cellular extracts, as assayed by Western blot, paralleled the amount of complex formed with the probe (Fig. 4B) . Since HNF4a7 contains 13 amino acids fewer than HNF4a1 at its N-terminus, the a7-a7 complex migrates marginally faster. The a445 antiserum supershifted both the a1-a1 and a7-a7 complexes (Fig. 4A, lanes 8 and 10) whereas the aN1.14 supershifted only the a1-a1 complex (Fig. 4A, lanes 7 and  9) . When NIH3T3 cells were transfected with expression vectors for both isoforms (Fig. 4A, lanes 3-5) , a retarded complex migrating between the a1-a1 and a7-a7 complexes appeared. This complex certainly contains dimers formed of HNF4a1 and HNF4a7. Co-transfections with varying amounts of the CMV.HNF4a7.VSV and a constant amount of CMV.HNF4a1.VSV were used to discriminate the three complexes. All complexes were supershifted by the a445 antiserum (data not shown) but the aN1.14 supershifted only the a1-a1 and a1-a7 complexes (Fig. 4A, lane 11) . Thus, HNF4a1 and HNF4a7 are able to dimerize when bound to DNA in spite of the presence of different N-terminal A/B domains which could introduce conformational changes. In addition, we assume that dimerization extends as well to HNF4a2 and HNF4a8, implying the existence of ten potential molecular entities concerning the four HNF4a isoforms in newborn liver.
Repression or activation of AFP expression parallels extinction or activation of HNF4a 7 transcripts
One of the few reliable markers of the fetal liver phenotype is AFP. Indeed, AFP is abundantly expressed throughout embryonic and fetal development, and the gene is actually switched off after birth, remaining silent during adult life except in some conditions of tumor pathology (reviewed in Kanduc et al., 1993; Mufti et al., 1991) . Determination of whether HNFa7/a8 are always present in AFPexpressing cells is an approach to test the functional repercussions of HNF4a7 promoter usage in developing liver. Total RNA from mouse liver at birth, at 2 weeks of age and from adult animals was examined for the expression of HNF4a isoforms and of AFP.
Even though HNF4a7/a8 are expressed abundantly during fetal liver development, exon 1D usage must decrease subsequently since it has been shown that adult liver expresses only very low levels of HNF4a7 compared to HNF4a1 (Nakhei et al., 1998) . Indeed, HNF4a7 expression is already diminished 2 days after birth and practically undetectable 2 weeks later (Fig. 5A) . Concomitantly, AFP HNF4a1.VSV or CMV.HNF4a7.VSV constructs. After 24 h, total cell extracts were prepared and 3 mg of protein were used for EMSA with the C3P oligonucleotide corresponding to the DNA binding element of HNF4 within the human ApoCIII promoter. For supershift assays, the aN1.14 (N) or a445 (C) was added. The shift reaction mixtures were resolved in a 10% PAGE. Lane 1 corresponds to non-transfected cells. The exposure was chosen for optimal resolution of the a1-a7 dimers. n.s., non-specific; s.s., supershift. (B) Five micrograms of the same cellular extracts used for EMSA were analyzed by Western blotting with an anti-VSV antibody to visualize the HNF4 protein.
transcripts were absent at the stages that were negative for HNF4a7 transcripts.
To test further this parallel, Fao hepatoma cells that express neither HNF4a7 nor AFP, were treated with TGFb to attempt to induce AFP expression. This growth factor has been shown to alter phenotypic traits of cultured hepatocytes (Mizuguchi et al., 1998; Sanchez et al., 1998) . Fao cells treated for 1 week with TGFb contained HNF4a7 transcripts in addition to the anticipated levels of HNF4a1; the same RNA samples revealed presence of AFP transcripts at a significant level (Fig. 5B) . Our results from both in vivo and in vitro analyses provide evidence of qualitative changes in AFP expression paralleled by repression (2 week old and adult liver) or activation (TGFb-treated Fao cells) of HNF4a7.
The existence of a correlation between the expression of HNF4a isoforms transcribed from different promoters and a fetal versus an adult hepatic phenotype led us to investigate whether this parallel reflects differences in the transcriptional properties of these isoforms. Indeed, in this case, it would be anticipated that genes that are precociously expressed (early genes) could be more efficiently transactivated by HNF4a7 than by HNF4a1 and the late genes could be subject to the opposite effect. To test this hypothesis, we analyzed the activity of both isoforms on HNF4 responsive reporter plasmids in co-transfection experiments.
2.6. HNF4a 7 activates more avidly than HNF4a1 reporter plasmids for early genes HNF4a deficient dedifferentiated H5 hepatoma cells and NIH3T3 fibroblasts were transfected with reporter constructs and either HNF4a1 or HNF4a7 cDNA, cloned in the same expression vector to permit comparisons. Western blots were performed in order to verify that the amounts of HNF4a1 and HNF4a7 were comparable within transfected cells (Fig. 6B) .
Reporter plasmids were chosen to illustrate a gene whose expression is extinguished in adult liver (AFP), one whose expression is strongly activated only after birth (ApoCIII; Haddad et al., 1986) , and one whose expression is characteristic of liver from early stages and throughout development (TTR).
The reporter containing the AFP promoter was reproducibly ðn ¼ 7Þ transactivated at least two-fold by HNF4a7, but not at all by HNF4a1, in both cell types (Fig. 6A) . Even though AFP has not been identified as a target gene for HNF4a, Nakabayashi et al. (NCBI accession number AB053573) have recently reported a DR-1 motif that binds HNF4 in the mouse AFP promoter. The gene coding for TTR contains well-characterized HNF4 sites within its promoter and enhancer (Costa et al., 1989) . In both cell types, HNF4a7 clearly transactivated more efficiently than HNF4a1 the reporter containing the promoter and enhancer of TTR (Fig. 6A) . Finally, the reporter construct containing the HNF4 binding sites from the ApoCIII promoter was much more efficiently transactivated by HNF4a1 than by HNF4a7 in both H5 and in NIH3T3 cells (Fig. 6A) .
Thus, both isoforms are transcriptionally active when tested in co-transfection but the activities they elicit differ depending on the reporter construct tested. When we analyzed the sequences responsible for HNF4 binding within these reporters, we did not find any evident correlation that could explain these differences. HNF4a7 transactivated better than HNF4a1 the reporters from early genes. These results provide a functional basis for the correlation observed between the expression of HNF4a7 or HNF4a1 and the phenotypic traits of the hepatoma cells where they are expressed. Most importantly, the transactivation efficiencies of HNF4a7 and HNF4a1 parallel their expression patterns in vivo during mouse liver development. 
Discussion
The establishment of the differentiated phenotype of a cell requires the coordinate expression of a set of specific transcription factors. The activities of these factors can be modulated by several types of mechanisms, including alternative splicing and transcription from alternative promoters. The results presented here show that for HNF4a expression there exist at least two different levels of regulation. The first level is tightly regulated and constitutive and involves alternative splicing resulting in differences within the Cterminal region of the protein. The HNF4a2 isoform, which contains an insertion of ten amino acids absent in HNF4a1, has been shown to be more efficiently co-activated by CBP, GRIP-1, and SRC-1 (Sladek et al., 1999) , and may be a more powerful transactivator. Consequently, the unvarying ratio of HNF4a1/a2 and HNF4a7/a8 assures a constant pool of the two forms that differ in their activities. The second mechanism that influences the activity of HNF4a is likely to be the most important for liver development and involves the usage of alternative promoters controlling the expression of exons 1D and 1A, resulting in the synthesis of the HNF4a7/a8 and HNF4a1/a2 isoforms, respectively.
HNF4a7 was initially described for an immortalized mouse embryonic hepatocyte line whose differentiation is inhibited by growth in serum containing medium; when serum was deleted, or dexamethasone added, the known HNF4a1 isoform was induced (Nakhei et al., 1998) . Hence, it appeared that HNF4a7 expression was associated with the dedifferentiated phenotype of these cells. In addition, HNF4a7 expression was detected in F9 teratocarcinoma cells and in ES cells, leading the authors to conclude that expression of this isoform could have a function during early embryogenesis. Finally, based upon cotransfection experiments with an HNF4 site from the a1-antitrypsin gene, it was concluded that the HNF4a7 variant has a significantly lower transactivation potential than HNF4a1 (Nakhei et al., 1998) .
For the well characterized hepatoma cell lines used here, we show that there is a strict correlation between the expression of HNF4a7 and a fetal hepatic phenotype, rather than between HNF4a7 and an undifferentiated phenotype. Cells that exhibit an adult hepatic phenotype express only HNF4a1. Significantly, the expression profile of both isoforms in vivo during liver development matches with the same pattern as hepatoma cells. In embryonic and early fetal liver HNF4a7 is abundant, the two isoforms are expressed around the time of birth and there is a quasi total extinction of HNF4a7 expression in adult liver.
To complete the picture of the composition of HNF4a in developing mouse liver, we show for transfected cell extracts that the HNF4a1 and HNF4a7 isoforms are able to form dimers, while Sladek et al. (1999) have shown that Fig. 6 . Transcriptional activity of HNF4a1 and HNF4a7. (A) H5 and NIH3T3 cells were transiently transfected with 5 mg of a reporter CAT construct containing regulatory sequences from the genes indicated and various amounts of the CMV.HNF4a1.VSV or CMV.HNF4a7.VSV constructs. The reporter constructs used contained: for AFP, the mouse alpha-fetoprotein promoter (21023/133); for TTR, mouse transthyretin promoter and distal enhancer; for ApoCIII, 2 C3P sites from the human apolipoprotein CIII promoter. Data are expressed as relative CAT activity normalized to internal control b-galactosidase activity. Results are the mean^SEM of at least three independent experiments. En, enhancer; Pro, promoter. (B) Western blot analysis of transfected HNF4a isoforms in H5 and NIH3T3 cells using an anti-VSV antibody. Cells were transfected with the indicated amounts of CMV.HNF4a1.VSV or CMV.HNF4a7.VSV vectors.
HNF4a1 and HNF4a2 can dimerize. This implies that for liver developmental stages where all four isoforms are expressed, up to ten combinations of HNF4a dimers could exist simultaneously.
It is essential to determine whether differences in transactivation and/or co-activation potential characterize the HNF4a isoforms. In order to evaluate transactivation potential, we have used co-transfection assays with two cell lines, dedifferentiated hepatoma and fibroblasts, to control for the possibility that differences observed could be due to accessory factors. Two particularly striking results were obtained. The HNF4 sites from the ApoCIII promoter are transactivated much more strongly by HNF4a1 than by HNF4a7; the ApoCIII gene is strongly up-regulated after birth, when HNF4a1/a2 become the exclusive forms. In other cases, HNF4a7 is a more avid transactivator than HNF4a1: with the promoter/enhancer combination from a gene that is activated early during liver development, TTR, and with the full-length AFP promoter. This last observation was strengthened by the finding that culture conditions that provoke the expression of HNF4a7 by hepatoma cells of adult phenotype induce in parallel AFP transcription. The long treatment time required for AFP activation is compatible with observations that efficient relief of gene silencing requires S-phase progression (Crowe et al., 2000) . Indeed, this may be true for both the AFP and HNF4a7, for both are subject to developmental silencing. The demonstration that transfected HNF4a1 and HNF4a7 can show functional differences on target sequences of reporter plasmids provides a first indication of the physiological roles of the isoforms resulting from alternative promoter usage.
It is known that physical interaction with nuclear receptor co-activators such as CBP is essential for HNF4a activity (Soutoglou et al., 2000) . CBP and GRIP-1 have previously been shown to interact with the A/B domain of HNF4a1, the most N-terminal module of the protein (Dell and Hadzopoulou-Cladaras, 1999; Wang et al., 1998) . In the case of HNF4a7, translation of exon 1D results in a shortened A/B domain whose ability to interact with co-activators remains to be tested. Indeed, since all HNF4a isoforms known to date share the same DNA binding domain and are likely to bind the same regulatory elements, their abilities to act as selective recruiters of co-activators could provide a basis for functional differences.
Since the HNF4a7 promoter is silenced after birth, it is likely to possess its own regulatory elements independent of those of HNF4a1. Exon 1D has not yet been mapped to genomic sequences in rodents. The HNF4a locus was mapped to human chromosome 20 (q12-q13.1) (Argyrokastritis et al., 1997) . To localize the exon 1D sequence within the genome, we performed Blast analysis between the rat exon 1D sequence (GeneBank AF329936) and human genomic sequences (NCBI database, accession number AL117382) and identified its human homolog to the same locus, 45.5 kb upstream from exon 1A (Fig. 1A) . This would imply that each promoter contains its own regulatory modules. The rat and mouse exons 1D and the human counterpart exhibit an identity in nucleotide sequence of 92% of the coding region, and 100% conservation of the deduced amino acids, revealing that this sequence has been highly conserved through evolution in mammals and it can therefore be assumed to perform a decisive role. In addition, HNF4a is not the only gene which plays a role in early endoderm development that possesses alternative promoters: GATA-6 and FTZ-F1 are both transcribed from two distinctively regulated promoters leading to proteins with different sizes (Brewer et al., 1999; Lin et al., 2000) . Indeed, alternative promoter usage can allow uncoupling of the mechanisms required for the initiation of gene expression from those required for maintenance of expression during adulthood. This property could confer flexibility to the regulation of genes important both during embryonic life and in the adult.
A different level of significance of the precocious expression of HNF4a7 and the neonatal augmentation of HNF4a1 expression could relate to the well documented network of LETF, where multiple levels of auto-regulation and crossregulation are observed (reviewed in Sladek and Seidel, 2001) . Indeed, how the initial activation of this group of factors is achieved remains unexplained. However, the uncoupling in the developing liver of activation of HNF4a7 and of HNF4a1 implies that the embryonic form could activate the downstream LETF HNF1a, and then at a later step, the two factors could act together to activate HNF4a1. This model is consistent with the binding sites documented in the HNF4a1 enhancer and its response to transactivation by HNF4a7 and HNF4a1 (Bailly et al., 2001) . Furthermore, these considerations lead us to question the finality of the conclusions drawn from the simultaneous targeted deletion of all HNF4a isoforms . Indeed isoform-specific deletions and replacements will be necessary to define whether HNF4a7 expression is indispensible for HNF4a1 activation, and whether the products of alternative promoter usage do or do not present overlapping activities in vivo.
HNF4a isoforms are differentially expressed during liver development and tests for transcriptional activity have revealed that they show differences. Indeed, the fact that HNF4 binding sites can differ not only in their composition but also in localization and neighboring sequences could confer mechanistic relevance to the temporal-regulation of HNF4a isoform expression. The differential and sequential expression of HNF4a7/a8 and HNF4a1/a2 during mouse liver development is the only modification in LETF thus far recorded that parallels the transition from the fetal to the adult hepatic phenotype.
Experimental procedures
Cell culture
Hepatoma cells and culture conditions have been described (Angrand et al., 1994; Faust et al., 1994) . NIH3T3 cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum. TGFb1 treatment of Fao cells was at 0.1 ng/ml TGFb1 (Sigma) with renewal of medium every 2 days. Fao cells die by apoptosis in the presence of TGFb, this concentration caused little or no cell death.
RNA extraction and Northern blot analysis
Total liver RNA was prepared from B6CBA mice as described by Chomczynski and Sacchi (1987) . RNA was extracted from cultured cells by the simplified phenolchloroform miniprep method. Northern blot analysis was performed as described by Chaya et al. (1997) using probes derived from the cDNA of HNF4a, AFP, TTR, PAH, and ribosomal 28S RNA (see Chaya et al., 1997) or ApoCIII, kindly provided by Mario Zakin, Institut Pasteur.
RT-PCR
Total RNA (5 mg) was treated with DNaseI (Amersham Pharmacia) and reverse-transcribed using random hexamers with the Superscript II Reverse Transcriptase (Gibco BRL). PCR (Eurobiotaq, Eurobio) was performed in the presence of 1 mCi [a- 
Plasmid constructs
The expression vector HNF4.tag containing the rat HNF4a1 cDNA driven by the CMV promoter of pCB6 (Brewer, 1994) has already been described (Späth and Weiss, 1997) , and will be hereafter referred to as CMV.HNF4a1.VSV. The CMV.HNF4a7.VSV plasmid was constructed as follows: cDNA from a rat hepatoma cell line known to express HNF4a7 (data not shown) was amplified by PCR with the primers 5 0 -CCGGAATTC-CATGCTCCCCAGTGTCCA, located in the 5 0 -UTR of HNF4a7, and 5 0 -GGCTCATCTCTGCTAGCTCTG containing the EcoRI and NheI sites, respectively. The PCR product was ligated into CMV.HNF4a1.VSV between the EcoRI site of the polylinker and the NheI site of the HNF4 coding region in order to replace the 5 0 HNF4a1 sequence.
The product was verified by sequencing. All the reporter plasmids contain the bacterial gene encoding chloramphenicol acetyltransferase (CAT). pHAF-CAT (Molne et al., 1989) contains the region from 21023 to 133 bp of the mouse AFP promoter; TTR promoter 1 enhancer-CAT, provided by Robert Costa (Costa et al., 1989) , contains the promoter and enhancer from the mouse TTR gene; APF1-HIV-CAT, provided by Frances Sladek (1990) , consists of two APF1 (C3P) oligonucleotides from the apolipoprotein CIII promoter in front of the human immunodeficiency virus long terminal repeat (LTR). The HNF4 binding sites within these plasmids and their localizations within the original promoters of the genes tested are: for the AFP reporter, 3 0 -AGGACAaAGACCA (2171 to 2159);
for the TTR reporter, 5 0 -GGCAAGgTTCATA (2154 to 2136); for the ApoCIII construction, 5 0 -TGGGCAaAG-GTCA (285 to 267).
Transfections and transactivation assays
Transient transfections were carried out by the calcium phosphate co-precipitation procedure and cells were harvested 48 h later. The reporter construct (5 mg) and various amounts of the CMV.HNF4a1.VSV or CMV.HNF4a7.VSV expression vectors were used; total DNA amount was equalized with the pCB6 plasmid and 5 mg of pMJM20 were added as an internal control for transfection. b-Galactosidase activity was measured by the standard colorimetric method and CAT assays were performed as described (Seed and Sheen, 1988) .
Protein extracts and electrophoretic mobility shift assays (EMSA)
Total cell extracts were prepared from transfected NIH3T3 cells as described by Jacquemin et al. (1999) . Extracts were prepared from B6CBA mice livers by boiling in 2% sodium dodecyl sulphate (SDS)-Tris-HCl buffer. Protein concentration was determined with the Bradford method. For EMSA, 3 mg of the total extracts from transfected cells were used (Cereghini et al., 1988) with the C3P probe corresponding to the HNF4 binding site (290 to 259 bp) of the human ApoCIII promoter (Mietus-Snyder et al., 1992) . For supershift assays, the shift reaction mixture was further incubated for 20 min at room temperature with 1 ml of a 1:10 dilution of the HNF4a1 N-terminal (aN1.14) antiserum (Sladek et al., 1999) or 1 ml of a 1:2.5 dilution of the HNF4a1 C-terminal (a455) antiserum (Sladek et al., 1990) , both kindly provided by Frances Sladek. Electrophoresis was carried out in a 10% acrylamide-bisacrylamide gel at 230 V for 8 h.
Western blotting
Extracts from livers or transfected cells were subjected to Tris-Glycine 9% polyacrylamide gel electrophoresis (PAGE)-SDS and blotted onto a nitrocellulose membrane (Sartorius AG). Primary antibodies were a monoclonal anti-VSV antibody coupled to peroxidase (1:2500, Boehringer Mannheim), the aN1.14 antiserum (1:10 000), or a-tubulin antibody (1:350, ICN) . When a secondary antibody was required a peroxidase-coupled goat anti-rabbit (1:20 000) was used. Peroxidase activity was detected by chemiluminiscence using the ECL kit (Amersham Pharmacia).
